Cancer vaccines: a promising cancer therapy against all odds (Q36839778)

16 August 2017

1 reference

title

Cancer vaccines: a promising cancer therapy against all odds (English)

1 reference

16 August 2017

Ann Willman Silk

1

1 reference

16 August 2017

Olivera J Finn

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

3

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

299-306

1 reference

Tumour stem cells and drug resistance

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Neoplastic stem cells: a novel therapeutic target in clinical oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Humoral immunity, inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Cancer immunotherapy: the past, the present and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Cancer vaccines: between the idea and the reality

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Colorectal cancer vaccines: principles, results, and perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

The first 1000 dendritic cell vaccinees.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Part I: Vaccines for solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Immune monitoring of T-cell responses in cancer vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcino

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Premalignant lesions as targets for cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

Regulatory T cells, tumour immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

21 January 2018

Cancer immunoprevention

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.3.299

21 January 2018

Identifiers

DOI

10.2217/14796694.3.3.299

1 reference

16 August 2017

1 reference